The medical technology company Marpe Technologies announced that its full-body Dermatology Screening System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The novel technology was designed to acquire and analyze full-body images of malignant and premalignant lesions, particularly melanoma, in adult patients. The system acquires dermoscopic views of suspicious lesions to provide clinicians with comprehensive information they can use to compare previous scans and refer patients for biopsy. Additionally, the system also stores all images for future use. “We believe that [the] Dermatology Screening System has the potential to revolutionize the way dermatological conditions are detected and treated,” concluded Yaakov Navon, PhD, Chief Technology Officer of Marpe Technologies. The FDA designation will facilitate a regulatory review process that will expedite the development and commercialization of the Dermatology Screening System.
August 02, 2023